Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: A randomised trial

Lancet

Volumn 359, Issue 9310, 2002, Pages 920-925

  Kastrati, Adnan ^a   Mehilli, Julinda ^a   Dirschinger, Josef ^a   Schricke, Ullrich ^a   Neverve, Jodi ^a   Pache, Jürgen ^a   Martinoff, Stefan ^a   Neumann, Franz Josef ^b   Nekolla, Stephan ^a   Blasini, Rudolf ^a   Seyfarth, Melchior ^b   Schwaiger, Markus ^a   Schömig, Albert ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DISEASE COURSE; FEMALE; FIBRINOLYSIS; FOLLOW UP; HEART MUSCLE REPERFUSION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SCINTIGRAPHY; SURVIVAL RATE;

EID: 0037117134     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08022-4     Document Type: Article

References (38)

1. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded?
2. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
3. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction
4. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
5. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy
6. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis
7. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction
8. Platelet function in acute myocardial infarction treated with direct angioplasty
9. Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction
10. Reperfusion revisited: Beyond TIMI 3 flow
11. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
12. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction
13. Potential non-glycoprotein IIb/IIIa effects of abciximab
14. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
15. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction
16. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
17. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
18. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTOV randomised trial
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
20. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents
21. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial
22. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile
23. Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction
24. Quantification of area at risk during coronary occlusion and degree of myocardial salvage after reperfusion with technetium-99m methoxyisobutyl isonitrile
25. Tc-99m sestamibi defect magnitude predicts the amount of viable myocardium after coronary reperfusion despite the presence of severe residual stenosis
26. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease
27. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction
28. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
29. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
30. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial, a randomized controlled trial
31. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction: Primary endpoint analysis from the CADILLAC trial
32. Acute myocardial infarction: Thrombolysis
33. Platelets and thrombolytic therapy
34. GPIIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
35. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: Role of selectins
36. Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition
37. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leukocyte interactions
38. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: Observations from the TIMI 14 trial